Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration
NCT: NCT07544667 · RECRUITING
Brief Summary
Pelvic organ prolapse (POP) is a condition characterized by descent of vaginal walls, uterus and cervix, or the perineum and causes a sensation of vaginal bulge and pelvic pressure. Millions of women in the United States are affected, and the number is expected to rise significantly in the coming decades. Current treatments either involve conservative measures or surgery. Surgery may lead to changes in vaginal topography and scar tissue, both of which impact sexual function. There are no treatment options that restore vaginal tissue strength and preserve, even optimize, sensation and blood flow to the vagina. This project will evaluate the use of poly-L-lactic acid (PLLA), an FDA-approved biostimulant for dermatologic use with an expansive safety profile over the past decade, in the treatment of anterior wall POP and its impact on sexual function. Our study will compare intravaginal injection of PLLA vs. placebo in women with stage 2 cystocele and investigate safety and preliminary efficacy of PLLA. Prior study of regenerative biologics for the vulva and vagina have shown great promise, but use of these has not been explored for POP. This randomized controlled trial has the potential to shift the paradigm of prolapse management from surgical reconstruction to regeneration. This shift will prevent the risks of surgery and has the potential to improve sexual function and quality of life by resolving POP.
Frequently Asked Questions
What is Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration?
Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration is a clinical trial registered under NCT07544667. Current status: RECRUITING.
What is the status of NCT07544667?
The current status of NCT07544667 (Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration) is: RECRUITING.
When did Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration start?
Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration started on 2026-05.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.